MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2022 International Congress

    Challenging diagnosis of familial Gerstmann-Straussler-Scheinker disease with normal brain image: a case report and systematic review

    KY. Park, SY. Jo, SJ. Chung (Seoul, Republic of Korea)

    Objective: We report a case of familial Gerstmann-Straussler-Scheinker (GSS) disease, who presented with cerebellar ataxia, but did not show abnormalities in diffusion weighted image (DWI)…
  • 2022 International Congress

    Protective effects of Hibiscus sabdariffa extracts in 6-hydroxydopamine-lesioned parkinsonism.

    A. Hamadjida, G. Ndji Otto, MK. Mingoas Kilekoung (bertoua, Cameroon)

    Objective: The therapeutic effects of Hibiscus sabdariffa (HS) were investigated in parkinsonism rats induced by 6-hydroxydopamine (6-OHDA). Background: The oxidative stress is an important component…
  • 2022 International Congress

    Association of glucocerebrosidase genotype and disease progression in early Parkinson’s disease over the course of 80 weeks

    H. Frequin, B. Ferwerda, C. Verschuur, S. Suwijn, J. Dijk, R. de Bie (Amsterdam, Netherlands)

    Objective: *Background and objectiveWe conducted post-hoc analyses with data of the Levodopa in EArly Parkinson’s disease (LEAP) study to compare the rate ofdisease progression in…
  • 2022 International Congress

    Beta-agonists and risk of Parkinson’s disease: Meta-analysis of real-world evidence studies

    A. Singh, S. Hussain, B. Antony (Hobart, Australia)

    Objective: We performed a systematic review and meta-analysis of real-world evidence (RWE) studies evaluating the association between use of beta-agonist and the risk of PD.…
  • 2022 International Congress

    Safety of opicapone after 5 years of post-marketing experience worldwide

    L. Guedes, J. Graça, M. Sampaio, M. Vieira, F. Rocha, H. Gama (Coronado, Portugal)

    Objective: To review the safety data of opicapone (OPC) after five years of marketing experience worldwide Background: OPC is a once-daily catechol-O-methyltransferase (COMT) inhibitor proven…
  • 2022 International Congress

    OCEAN Study in Parkinson’s Disease: Status Update of a Randomised Double-Blind Placebo-Controlled Trial of Opicapone

    K. Chaudhuri, P. Odin, J. Ferreira, A. Antonini, O. Rascol, M. Kurtis, A. Storch, K. Bannister, R. Costa, D. Magalhães, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: This study aims to evaluate if treatment with opicapone (OPC) 50 mg once-daily can improve motor fluctuation (MF)-related pain in patients with Parkinson’s disease…
  • 2022 International Congress

    Variability in Age of Onset, Age of Diagnosis and Age of Death for Progressive Supranuclear Palsy Patients Among Three Racial Groups in Hawai`i

    A. Kannan, F. Gao, G. Fujikami, M. Bruno (Honolulu, USA)

    Objective: To examine if differences in age of symptom onset, age of diagnosis, age of death, and number of years lived after diagnosis exist for…
  • 2022 International Congress

    Perception-action binding in patients with functional movement disorders

    J. Moyé, F. Chwolka, T. Paulus, S. Zittel, J. Verrel, T. Bäumer, A. Münchau, A. Weissbach (Lübeck, Germany)

    Objective: To analyze cognitive processes engaged in linking and restructuring sensory perception and motor action associations in functional movement disorders (FMD). Background: FMD patients demonstrate…
  • 2022 International Congress

    Patients with Parkinson’s Disease Share a Unique Olfactory Perceptual Fingerprint

    M. Andelman-Gur, K. Snitz, A. Ravia, N. Hezi, A. Ezra, D. Klepikov, T. Gurevich, N. Sobel (Rehovot, Israel)

    Objective: To explore potential olfactory biomarkers for early detection of Parkinson's disease Background: Although the olfactory decline in Parkinson’s disease (PD) precedes the motor symptoms…
  • 2022 International Congress

    ‘Top of the POPPS’ – how we set up an online support group for Partners of People with Parkinson’s.

    E. Edwards, S. Austin, J. Friend (Plymouth, United Kingdom)

    Objective: To provide useful peer and professional support for partners of people with Parkinson's (PWP)To be able to offer that support in a Covid safe…
  • « Previous Page
  • 1
  • …
  • 57
  • 58
  • 59
  • 60
  • 61
  • …
  • 153
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley